Champions Oncology, Inc. (CSBR) stock
CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jul 31, 2026Last filing: 10-Q on Sep 11, 2026Score 10/30238% above fair value
$4.44−0.15 (-3.30%)
Close on Nov 18, 2026Market cap $61.80MP/E –Yield –
Champions Oncology pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Champions Oncology's pe ratio was 35.0× on Feb 27, 2026, against 465.0× a year earlier. Over the last 3 years it ranged from 13.3× to 977.0×, with a median of 250.0×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Feb 27, 2026 | 35.0× | −5.6 |
| 2025 | Dec 31, 2025 | 40.6× | −424.4 |
| 2023 | Feb 28, 2023 | 465.0× | +14.0 |
| 2022 | Dec 30, 2022 | 451.0× | +172.3 |
| 2021 | Dec 31, 2021 | 278.7× | −261.3 |
| 2019 | Aug 30, 2019 | 540.0× | – |
See a number that looks wrong?